Triple Agonist
An investigational drug class activating GLP-1, GIP, and glucagon receptors at once — retatrutide is the flagship.
Triple agonists extend the stacking logic one receptor further: GLP-1 for appetite and satiety, GIP for insulin and energy handling, and glucagon for raised energy expenditure. One molecule, three signals — appetite down, storage rebalanced, burn rate up.
Retatrutide's phase 2 average of roughly 24% at 48 weeks, on a still-falling curve, suggested the class could approach bariatric-surgery territory pharmacologically. None is yet approved, so the practical takeaway for patients is orientation rather than action: the treatment landscape is mid-leap, and a plan that works today can be revisited as stronger tools clear trials.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Triple Agonist? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment